Targeting nanoparticles across the blood-brain barrier with monoclonal antibodies.

Abstract

Development of therapeutics for brain disorders is one of the more difficult challenges to be overcome by the scientific community due to the inability of most molecules to cross the blood-brain barrier (BBB). Antibody-conjugated nanoparticles are drug carriers that can be used to target encapsulated drugs to the brain endothelial cells and have proven to be very promising. They significantly improve the accumulation of the drug in pathological sites and decrease the undesirable side effect of drugs in healthy tissues. We review the systems that have demonstrated promising results in crossing the BBB through receptor-mediated endocytic mechanisms for the treatment of neurodegenerative disorders such as Alzheimer's and Parkinson's disease.

• Authors: Joana A Loureiro, Bárbara Gomes, Manuel A N Coelho, Maria do Carmo Pereira, Sandra Rocha
• Journal: Nanomedicine (London, England) (Nanomedicine (Lond)) Vol. 9 Issue 5 Pg. 709-22 (Apr 2014) ISSN: 1748-6963 [Electronic] England
• PMID: 24827845 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antibodies, Monoclonal
• Nanocapsules
• Neuroprotective Agents

Topics

• Animals
• Antibodies, Monoclonal (administration & dosage, pharmacokinetics)
• Blood-Brain Barrier (metabolism)
• Drug Compounding (methods)
• Drug Delivery Systems (methods)
• Humans
• Nanocapsules (chemistry, ultrastructure)
• Neurodegenerative Diseases (drug therapy, metabolism)
• Neuroprotective Agents (administration & dosage)